PEPTIDES,
Red Flag
Peptide red-flag dashboard with cheat sheet
Source-linked panels
The harshest red flags right now are GLP-1 drugs for gut-motility injury, MK-677 for insulin resistance and edema, and BPC-157/TB-500 for evidence weakness plus tumor-support concern.
This version folds the one-page cheat sheet into the dashboard so you can move from summary to ranking to detailed damage descriptions without leaving the same file.
Fast take
What matters most
- GLP-1 drugs: strongest current human concern for delayed gastric emptying, obstruction-type illness, vomiting, and dehydration fallout.
- Compounded GLP-1: same class risks plus purity, dosing, and sameness uncertainty.
- BPC-157 / TB-500: weakest long-term human evidence, with double-edged repair pathways.
- MK-677: strongest metabolic caution for appetite, edema, insulin resistance, and glucose drift.
Blunt ranking
Fast comparison from the cheat sheet
| Peptide / class | Main red flag | Short use summary | Why it matters | Caution |
|---|---|---|---|---|
| GLP-1 drugs | Gastroparesis, ileus, obstruction, vomiting | Used for diabetes, obesity, and weight-loss-driven cardiometabolic risk reduction. | Can escalate from “GI side effects” to retained stomach contents, dehydration, ER visits, aspiration risk, and hospitalization. | Highest gut risk |
| Compounded GLP-1 | Class risks plus product uncertainty | Used as lower-cost or access-driven alternatives to branded weight-loss and diabetes drugs. | Purity, dosing, and sameness concerns are layered on top of normal GLP-1 risk. | Highest uncertainty |
| BPC-157 | Evidence weakness, angiogenesis/remodeling concern | Marketed for tendon, ligament, gut, ulcer, and injury recovery. | Healing pathways may also support unwanted tissue behavior; long-term human safety is thin. | Unknown long-run biology |
| TB-500 | Evidence weakness, cell migration concern | Marketed for muscle, fascia, tendon, ligament, mobility, and recovery support. | Very weak human long-term safety support despite widespread hype. | Experimental use |
| CJC-1295 / Ipamorelin | GH/IGF-1 signaling | Marketed for GH support, body composition, recovery, sleep, and anti-aging. | Edema, numbness, joint issues, and glucose disturbance are the main concern pattern. | High caution |
| MK-677 | Insulin resistance, appetite spike, edema | Marketed for muscle growth, GH/IGF-1 elevation, sleep, recovery, and appetite increase. | Can push the user toward worse glucose control, more water retention, and unwanted weight gain. | Highest metabolic harm |
GLP-1 drugs
What damage they can actually do
- Delayed gastric emptying can become gastroparesis-like illness with nausea, vomiting, retained food, reflux, and obstruction-type symptoms.
- Gallbladder injury can include sludge, stones, inflammation, pain crises, infection risk, and sometimes surgery.
- Pancreatitis means real pancreatic inflammation and injury, with severe pain, vomiting, hospitalization, and rare necrosis or death.
- Kidney injury is often indirect, driven by dehydration and low intake.
BPC-157 / TB-500
What gets left out
- The largest problem is weak long-term human evidence.
- Their “healing” rationale relies on angiogenesis, nitric oxide signaling, remodeling, and cell migration.
- Those same pathways can be double-edged and may support abnormal vessel growth or tumor-friendly biology in the wrong setting.
- Users are often functioning as self-experimenters without robust surveillance.
CJC-1295 / Ipamorelin
Growth-signaling damage pattern
- Fluid retention and edema.
- Joint discomfort and tingling or numbness.
- Worse glucose handling in some users.
- Theoretical concern about supporting preexisting malignancy through GH/IGF-1 pathways.
MK-677
Metabolic damage pattern
- Appetite increase that can work directly against fat loss.
- Water retention and edema.
- Insulin resistance and worse glucose control.
- Possible support of occult tumor growth through GH/IGF-1 physiology rather than proof of creating a new cancer outright.
Current uses on the market
What each peptide is currently sold, prescribed, or promoted for
| Peptide / class | Current market use | Status / context |
|---|---|---|
| Semaglutide | Type 2 diabetes, chronic weight management, and cardiovascular-risk reduction in certain adults with overweight or obesity. | FDA-approved branded drug use; also widely discussed in compounding markets. |
| Tirzepatide | Type 2 diabetes and chronic weight management in adults with obesity or overweight plus at least one weight-related condition. | FDA-approved branded drug use; demand also drove compounded-market activity. |
| BPC-157 | Marketed for tendon repair, ligament recovery, gut healing, ulcer support, joint pain, and post-injury recovery. | Primarily wellness-clinic and gray-market promotion, not mainstream FDA-approved use. |
| TB-500 | Marketed for muscle, fascia, tendon, and ligament healing, flexibility, mobility, inflammation control, and recovery support. | Primarily performance / recovery marketing rather than approved medical use. |
| CJC-1295 | Marketed for growth-hormone stimulation, body-composition support, muscle gain, recovery, and sleep support. | Commonly sold in hormone / peptide clinics, often stacked with ipamorelin. |
| Ipamorelin | Marketed for growth-hormone pulses, fat loss, sleep, recovery, anti-aging, and lean-mass support. | Usually paired with CJC-1295 in peptide-clinic offerings. |
| MK-677 | Marketed for muscle growth, GH/IGF-1 elevation, appetite increase, recovery, sleep, and “hormonal support.” | Often promoted as the oral convenience option in performance and longevity circles. |
Avoid / maybe / strongest caution
Decision view from the cheat sheet
| Class | Practical read |
|---|---|
| GLP-1 drugs | Maybe — only if the benefit case is strong enough to justify real gut, gallbladder, pancreatic, and dehydration-related risk. |
| Compounded GLP-1 | Strongest caution — class risk plus product-quality and dosing uncertainty. |
| BPC-157 | Strongest caution — long-term human safety confidence is too weak. |
| TB-500 | Avoid / strongest caution — close to experimental self-administration. |
| CJC-1295 / Ipamorelin | Strong caution — especially if edema, glucose control, or malignancy risk already matters. |
| MK-677 | Avoid or strongest caution — especially for anyone worried about insulin resistance or metabolic backsliding. |
Clickable source bank
Direct article and regulator links collected in one place